Endometrics is a biotechnology startup founded in 2021 with the slogan "Time to end the silence". The company is headquartered in the United States and is dedicated to developing a new genomic biomarker for the early detection of endometriosis.
Their most recent milestone includes securing Pre Seed Round investment on 01 January 2022 from Flatiron Investors. This financial backing signifies a vote of confidence from the venture capital community and provides Endometrics with crucial resources to drive their groundbreaking research forward.
With the rising importance of women's health in the healthcare industry, Endometrics' innovative approach to addressing endometriosis presents a compelling investment opportunity for venture capitalists looking to support cutting-edge advancements in both biotechnology and healthcare.